Trial results

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

NCT07285902 on ClinicalTrials.gov · last registry update 2026-02-27

Closed to new participants; the 572 already enrolled are still being followed. Due to report March 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Percentage change from baseline in body weight after 52 weeks of treatment. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.

Sponsor type

Industry

Enrollment

572

Started

2025-12-25

Primary completion

2027-03 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage change from baseline in body weight after 52 weeks of treatment

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.